



#8
I hereby certify that this correspondence is being deposited with the United States Patent Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231
on January 1, 2002
By: Debbie Ellis
Printed: Debbie Ellis

030
COPY OF PAPERS
ORIGINALLY FILED

Docket No.: PA-0033 US

1645

RECEIVED

FEB 07 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schebye et al.

Title: cDNAs EXPRESSED IN ADIPOCYTE DIFFERENTIATION

Serial No.: 09/918,624 Filing Date: July 30, 2001

Examiner: To Be Assigned Group Art Unit: 1645

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual

of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date:

January 19, 2003 *for* *David S. Strulz Reg. No. 43,168*
Lynn E. Murry, Ph.D.
Reg. No. 42,918
Direct Dial Telephone: (650) 845-4159

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office		Atty Docket No.	Serial No.
		PA-0033 US	10316 624
LIST OF REFERENCES CITED BY APPLICANTS <i>(use several sheets if necessary)</i>		Applicant(s)	RECEIVED
<i>FEB 04 2002</i>		Schebye et al.	<i>FEB 07 2002</i>
		Filing Date	TECH CENTER 1600/290C
		July 30, 2001	1645

OIP SC PARENT & TRADEMARK OFFICE

U.S. Patent Documents

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
-------------------	--	-----------------	------	------	-------	----------	----------------------------

Foreign Patent Documents

Translation

		Document	Date	Country	Class	Subclass	Yes	No
--	--	----------	------	---------	-------	----------	-----	----

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Adams, M. et al., "Activators of Peroxisome Proliferator-activated Receptor γ Have Depot-specific Effects on Human Preadipocyte Differentiation", <u>J. Clin. Invest.</u> , 100:3149-3153 (1997)
2	Pickup, J.C. and M.A. Crook, "Is Type II diabetes mellitus a disease of the innate immune system?", <u>Diabetologia</u> , 41:1241-1248 (1998)
3	Skolnik, E.Y. and J. Marcusohn, "Inhibition of Insulin Receptor Signaling by TNF: Potential Role in Obesity and Non-Insulin-Dependent Diabetes Mellitus", <u>Cytokine Growth Factor Rev.</u> , 7:161-173 (1996)
4	Hotamisligil, G.S., "The role of TNF α and TNF receptors in obesity and insulin resistance", <u>J. Intern. Med.</u> , 245:621-625 (1999)
5	Murphy, M. et al., "Suppression Subtractive Hybridization Identifies High Glucose Levels as a Stimulus for Expression of Connective Tissue Growth Factor and Other Genes in Human Mesangial Cells", <u>J. Biol. Chem.</u> , 274:5830-5834 (1999)
6	Sharma, K. et al., "TGF- β in diabetic kidney disease: role of novel signaling pathways", <u>Cytokine Growth Factor Rev.</u> , 11:115-123 (2000)
7	McKenzie, A.N.J. et al., "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function", <u>Proc. Natl. Acad. Sci. USA</u> , 90:3735-3739 (1993)
8	Punnonen, J. et al., "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells", <u>Proc. Natl. Acad. Sci. USA</u> , 90:3730-3734 (1993)
9	Donaldson, D.D. et al., "The Murine IL-13 Receptor $\alpha 2$: Molecular Cloning, Characterization, and Comparison with Murine IL-13 Receptor $\alpha 1$ ", <u>J. Immunol.</u> , 161:2317-2324 (1998)

Examiner	Date Considered
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.